Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1267095.RAtdzcCLIzdpqJEKZfyb9aNiU-xUH3gpXOuxhZxo62Ntk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1267095.RAtdzcCLIzdpqJEKZfyb9aNiU-xUH3gpXOuxhZxo62Ntk130_assertion type Assertion NP1267095.RAtdzcCLIzdpqJEKZfyb9aNiU-xUH3gpXOuxhZxo62Ntk130_head.
- NP1267095.RAtdzcCLIzdpqJEKZfyb9aNiU-xUH3gpXOuxhZxo62Ntk130_assertion description "[Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment is the standard therapy for non-small cell lung cancer (NSCLC) harbouring EGFR-activating mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1267095.RAtdzcCLIzdpqJEKZfyb9aNiU-xUH3gpXOuxhZxo62Ntk130_provenance.
- NP1267095.RAtdzcCLIzdpqJEKZfyb9aNiU-xUH3gpXOuxhZxo62Ntk130_assertion evidence source_evidence_literature NP1267095.RAtdzcCLIzdpqJEKZfyb9aNiU-xUH3gpXOuxhZxo62Ntk130_provenance.
- NP1267095.RAtdzcCLIzdpqJEKZfyb9aNiU-xUH3gpXOuxhZxo62Ntk130_assertion SIO_000772 25726043 NP1267095.RAtdzcCLIzdpqJEKZfyb9aNiU-xUH3gpXOuxhZxo62Ntk130_provenance.
- NP1267095.RAtdzcCLIzdpqJEKZfyb9aNiU-xUH3gpXOuxhZxo62Ntk130_assertion wasDerivedFrom befree-2016 NP1267095.RAtdzcCLIzdpqJEKZfyb9aNiU-xUH3gpXOuxhZxo62Ntk130_provenance.
- NP1267095.RAtdzcCLIzdpqJEKZfyb9aNiU-xUH3gpXOuxhZxo62Ntk130_assertion wasGeneratedBy ECO_0000203 NP1267095.RAtdzcCLIzdpqJEKZfyb9aNiU-xUH3gpXOuxhZxo62Ntk130_provenance.